Table 6 Immunosuppression in patients with pre-OLT renal dysfunction associated with recovery of renal function post-OLT
|  | Recovery of renal function (n = 863) | Non-recovery (n = 857) | p | OR (95% CI) |
|---|---|---|---|---|
Anti-thymocyte globulin induction | 34 (4%) | 16 (1.8%) | 0.014 | 2.15 (1.2-4.0) |
OKT3 | 20 (2.3%) | 20 (2.3%) | 0.90 | 0.99 (0.53-1.73) |
Basiliximab | 26 (3%) | 32 (3.7%) | 0.69 | 0.80 (0.55-1.50) |
Daclizumab | 20 (2.3%) | 31 (3.6%) | 0.27 | 0.74 (0.43-1.27) |
Alemtuzumab | 1 (0.1%) | 2 (0.2%) | 0.54 | 0.50 (0.44-5.30) |
Cyclosporine | 188 (22%) | 192 (22%) | 0.75 | 0.96 (0.76-1.21) |
Tacrolimus | 437 (51%) | 479 (56%) | 0.029 | 0.81 (0.67-0.97) |
Sirolimus | 21 (3%) | 23 (2.7%) | 0.74 | 0.87 (0.81-1.23) |